Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors

NCT00305084 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: NGR-hTNF
DRUG: Doxorubicin

Sponsor

AGC Biologics S.p.A.